Mineralys Therapeutics (NASDAQ:MLYS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Mineralys Therapeutics (NASDAQ:MLYS) from a sell rating to a hold rating in a research note issued to investors on Sunday morning.

Several other research firms also recently weighed in on MLYS. Stifel Nicolaus increased their price objective on Mineralys Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a report on Friday, December 19th. Bank of America lifted their target price on shares of Mineralys Therapeutics from $46.00 to $51.00 and gave the company a “buy” rating in a report on Friday. Jefferies Financial Group reiterated a “hold” rating and issued a $30.00 price target on shares of Mineralys Therapeutics in a research report on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mineralys Therapeutics in a research note on Thursday, January 22nd. Finally, HC Wainwright set a $56.00 price objective on shares of Mineralys Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, March 10th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Mineralys Therapeutics has an average rating of “Moderate Buy” and an average price target of $49.14.

Mineralys Therapeutics Stock Performance

Mineralys Therapeutics stock opened at $25.02 on Friday. Mineralys Therapeutics has a fifty-two week low of $10.44 and a fifty-two week high of $47.65. The company has a market capitalization of $2.06 billion, a P/E ratio of -10.56 and a beta of 0.57. The stock has a 50-day simple moving average of $30.04 and a 200-day simple moving average of $35.79.

Mineralys Therapeutics (NASDAQ:MLYS) last released its quarterly earnings results on Thursday, March 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.17. As a group, analysts forecast that Mineralys Therapeutics will post -4.23 earnings per share for the current year.

Insiders Place Their Bets

In other Mineralys Therapeutics news, CEO Jon Congleton sold 16,236 shares of the business’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $32.62, for a total value of $529,618.32. Following the sale, the chief executive officer directly owned 639,151 shares in the company, valued at approximately $20,849,105.62. The trade was a 2.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David Malcom Rodman sold 14,058 shares of the company’s stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $26.26, for a total transaction of $369,163.08. Following the completion of the sale, the insider directly owned 76,140 shares of the company’s stock, valued at $1,999,436.40. The trade was a 15.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 363,325 shares of company stock worth $12,298,347 in the last three months. Company insiders own 33.24% of the company’s stock.

Hedge Funds Weigh In On Mineralys Therapeutics

Several hedge funds have recently made changes to their positions in MLYS. RA Capital Management L.P. lifted its stake in Mineralys Therapeutics by 19.1% during the third quarter. RA Capital Management L.P. now owns 7,323,750 shares of the company’s stock valued at $277,717,000 after purchasing an additional 1,176,470 shares during the last quarter. Vanguard Group Inc. grew its position in Mineralys Therapeutics by 11.1% in the fourth quarter. Vanguard Group Inc. now owns 3,352,880 shares of the company’s stock worth $121,676,000 after buying an additional 333,881 shares during the last quarter. State Street Corp increased its holdings in shares of Mineralys Therapeutics by 144.4% in the fourth quarter. State Street Corp now owns 3,184,999 shares of the company’s stock valued at $115,584,000 after buying an additional 1,881,976 shares in the last quarter. Caligan Partners LP increased its holdings in shares of Mineralys Therapeutics by 37.4% in the third quarter. Caligan Partners LP now owns 2,772,654 shares of the company’s stock valued at $105,139,000 after buying an additional 755,302 shares in the last quarter. Finally, Suvretta Capital Management LLC lifted its position in shares of Mineralys Therapeutics by 22.2% during the 3rd quarter. Suvretta Capital Management LLC now owns 2,132,133 shares of the company’s stock valued at $80,850,000 after acquiring an additional 387,641 shares during the last quarter. Institutional investors and hedge funds own 84.46% of the company’s stock.

More Mineralys Therapeutics News

Here are the key news stories impacting Mineralys Therapeutics this week:

• Positive Sentiment: Company said it advanced regulatory review of its hypertension candidate and reported 2025 results, which supports the clinical/regulatory story underpinning long‑term value. Mineralys reports 2025 results, advances hypertension drug review
• Positive Sentiment: HC Wainwright raised FY2030 and FY2029 EPS estimates and maintains a “Buy” rating with a $56 target, signaling rising sell‑side expectations for multi‑year profitability (FY2030 EPS raised to $4.55; FY2029 to $1.56).
• Positive Sentiment: Recent quarterly report (Mar 12) beat consensus on EPS: reported ($0.40) vs. consensus ($0.57), showing better near‑term operating performance than modeled by some analysts.
• Neutral Sentiment: Institutions have been active — several funds added positions and Goldman Sachs materially increased its stake — which can lend stability but also reflects varied institutional views; consensus price target remains elevated versus current trading levels.
• Negative Sentiment: Insider selling: Director/officer David Malcom Rodman has sold multiple large blocks in March (most recently 6,348 and 14,058 shares), which may worry investors about near‑term insider conviction. MLYS Insider Selling
• Negative Sentiment: Technical/price pressure: shares are trading below the 50‑day and 200‑day moving averages and have declined today, reflecting short‑term selling despite positive fundamentals; consensus near‑term EPS remains negative (market consensus ~ -$4.23 for the current year), keeping risk elevated for investors.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.